NCT06469281View on ClinicalTrials.gov

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

May 27, 2030

Study Completion Date

May 27, 2030

Conditions
Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube Cancer
Interventions
OTHER

27T51

Intravenous (IV) infusion

DRUG

Cemiplimab

IV infusion

DRUG

Bevacizumab

IV Infusion

Trial Locations (4)

14203

RECRUITING

Roswell Park Cancer Institute, Buffalo

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

02114

RECRUITING

Massachusetts General Hospital, Boston

07601

RECRUITING

John Theurer Cancer Center Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY